In the final part of our ACR 2020 highlights series, Peter C Taylor (University of Oxford, Oxford, UK) reviews the results from an observational multicentric study investigating the efficacy and safety of a second jakinib in patients who failed to respond, or had side effects, from a previous jakinib.
The abstract entitled ‘Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis’ was presented at ACR Convergence 2020.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatoid Arthritis
NRAS’s mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society
We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS’s profound impact on the RA community, and her role and experiences within the NRAS, and pivotal contributions to pioneering […]
A patient’s perspective – journey to diagnosis of seronegative rheumatoid arthritis: Ailsa Bosworth, National Rheumatoid Arthritis Society
We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the […]
Peter Taylor, EULAR 2023: Current perspectives on the selectivity and safety of JAK inhibitors to target the pathophysiology of rheumatoid arthritis
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]